FDA convenes committee of vaccine experts to consider a flu-like path for Omicron-specific boosters
Although the FDA signed off last week on a second Covid-19 booster shot for those who are over 50 years old, without first consulting its advisory committee of outside vaccine experts, the agency is convening the committee on Wednesday — as was planned prior to the second booster decision — to discuss next steps for an Omicron- or other variant-specific booster.
While the currently authorized and approved Covid vaccines (from Pfizer, Moderna and J&J) are designed to elicit a protective response to the virus that circulated early on in the pandemic, the accumulating data suggest that the composition of vaccines may need to be updated, the FDA said ahead of tomorrow’s meeting, “at some point to ensure the high level of efficacy demonstrated in the early vaccine clinical trials.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.